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RNA interference is a powerful genetic approach for efficiently
silencing target genes. The existing method of gene suppression by
the constitutive expression of short hairpin RNAs (shRNAs) allows
analysis of the consequences of stably silencing genes but limits
the analysis of genes essential for cell survival, cell cycle regulation,
and cell development. We have developed an inducible U6 pro-
moter for synthesis of shRNAs in both human and murine cells.
Cells containing stably integrated shRNA expression constructs
demonstrate stringent dosage- and time-dependent kinetics of
induction with undetectable background expression in the absence
of the inducer ecdysone. Inducible suppression of human p53 in
glioblastoma cells shows striking morphological changes and de-
fects in cell cycle arrest caused by DNA damage, as expected.
Remarkably, the inducibility is reversible after withdrawal of the
inducer, as observed by reappearance of the protein and a resto-
ration of the original cell phenotype. Inducible and reversible
regulation of RNA interference has broad applications in the areas
of mammalian genetics and molecular therapeutics.
The ability to vary expression levels of an endogenous geneproduct at will and to monitor effects on cells or whole
animals can provide powerful insights into its biological role.
RNA interference (RNAi)-mediated gene silencing has emerged
as a powerful approach to regulate levels of an endogenous
protein within its physiological limits.
RNAi is a process of sequence-specific posttranscriptional gene
silencing mediated by double-stranded RNA and is a powerful
genetic approach to analyze gene function in many organisms (1, 2).
The endogenous mediators of sequence-specific mRNA degrada-
tion are 21- and 22-nt short interfering RNAs (siRNAs) generated
from longer double-stranded RNAs by the ribonuclease III activity
of the evolutionary conserved dicer enzyme (3, 4). Gene-specific
long double-stranded RNAs have been successfully used in worms
and flies for RNAi-mediated gene silencing (5). However, in
mammalian cells, double-stranded RNAs 30 bp trigger the anti-
viralIFN pathways that results in global shut-down of protein
synthesis (6, 7). Recently it was demonstrated that RNAi-mediated
gene silencing can be obtained in cultured mammalian cells by
delivery of chemically synthesized short (30 nt) double-stranded
siRNA molecules (3) or by endogenous expression of short hairpin
RNAs (shRNAs) bearing a fold-back stem-loop structure (8–12).
Plasmid- and viral vector-based constitutive expression of
shRNAs by RNA polymerase III U6 and H1 small nuclear RNA
promoters (U6 or H1) often result in stable and efficient
suppression of target genes (9, 10, 13). However, the inability to
adjust levels of suppression has imposed limitations in the
analysis of genes essential for cell survival, cell cycle regulation,
and cell development. Besides, gross suppression of a gene for
longer periods may result in nonphysiological responses. This
problem can be circumvented by generating inducible regulation
of RNAi in mammalian cells. The two most widely used induc-
ible mammalian systems use tetracycline- or ecdysone-
responsive transcriptional elements (14, 15). The chief drawback
of the tetracycline-inducible system is a relatively high back-
ground of expression in the uninduced state in certain cell lines
(15, 16). The ecdysone-inducible system is tightly regulated (15,
17), with no expression in the uninduced state and a rapid
inductive response (15), and the components of the inducible
system are inert with rapid clearance kinetics and, therefore, do
not affect mammalian physiology.
To facilitate stable and inducible suppression of any gene we
have developed an ecdysone-inducible synthesis of shRNAs
under the control of a modified RNA polymerase III-specific U6
promoter. By using a retroviral delivery and fluorescence-
activated cell sorting (FACS) analysis of enhanced GFP (EGFP)
positive cells, stable cell lines were rapidly and efficiently estab-
lished both in murine and human cells, thus alleviating the
labor-intensive isolation and analysis of multiple independent
clones. Significantly, RNAi inducibility follows a stringent dose-
and time-dependent kinetics of induction with undetectable
background expression in the absence of the inducer. We
inducibly expressed shRNAs targeting the human tumor sup-
pressor p53 gene in the human glioblastoma cell line and MyoD
in the murine endothelial cell line. Dose- and time-dependent
suppression of p53 gene expression was associated with changes
in cell morphology and concomitant reduction in its downstream
target p21. Furthermore, the suppression was specific because
it could override p53-dependent cell cycle arrest caused by
-irradiation. Remarkably, withdrawal of the inducer completely
reversed the phenotype as indicated by reappearance of the
protein, a restoration of original morphology, and a gain in the
ability to undergo p53-mediated cell cycle arrest in response to
-irradiation. An inducible regulation of RNAi with reversible
properties has broad implications in the areas of mammalian
genetics and molecular therapeutics.
Materials and Methods
Generation of Retroviral Constructs. Retroviral vectors expressing
the two nuclear receptortranscription factors, VgEcR and
RXR, were constructed as described (17). To construct pEind-
RNAi, a GAL4-Oct-2Q(Q 3 A) fragment was PCR-amplified
from pCG-GAL4-Oct-2Q(Q 3 A) (18) by using a forward
primer (ACGCCCGCGGATGAAGCTACTGTCTTCTATC)
and reverse primer (CACCCTGAAGTTCTCAGGATCC), di-
gested with SacIIBamHI, and inserted into the SacIIBamH1
site upstream of vector pIRES-EGFP (Clontech). Next, the
GAL4-Oct-2Q(Q 3 A) internal ribosomal entry site-linked
EGFP was PCR-amplified by using a forward primer (AGCTT-
TGTTTAAACCGAATTCTGCAGTCGACGGTA) and re-
verse primer CAGCTGATCATTA CTTGTACAGCTCGTCC,
digested with PmeIBclI, and inserted into the PmeIBclI site of
pI-TKHygro retroviral vector (17). Next, a BglII site was created
downstream of XhoI in pI-TKHygro by site-directed mutagenesis
(Stratagene) by using two primers: ACAGTGGCGGCCGCTC-
GAGATCTCTTGGAGTGGTGAATCCGTT (upper) and
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TGTCACCGCCGGCGAGCTCTAG AGAACCTCACCACT-
TAGGCAA (lower). The resulting construct was digested with
BglII and blunt-ended with Klenow enzyme into which a gateway
destination cassette ccdB (Invitrogen) was inserted.
To generate 4XGAL4 DNA-binding sites upstream of the U6
promoter-containing vector (19), a SacI site was created by
site-directed mutagenesis (Stratagene) upstream of the Oct-1-
binding site by using two primers, CAGGCTCCGCGGCCGC-
CGAGCTCACCGAGGGCCTATTTCCCATG (upper) and
GTCCGAGGCGCCG GC GGCTCGAGTGGCTCCCG-
GATAAAGGGTAC (lower). The Oct-1 and staf binding ele-
ments were removed by digestion with SacINdeI and replaced
with 4XGAL4-binding sites obtained by digesting vector pU6-
198-4XG17M (18) with SacINdeI.
Designing and Cloning of shRNAs. A majority of shRNA probes
were designed by using computer software (www.cshl.org
publicSCIENCEhannon.html). shRNA sequences (two com-
plementary 83-nt DNA oligos) were annealed and cloned
directly into a 4XGAL4 U6 promoter-containing vector by using
a ligation-independent cloning method (19). The entire
4XGAL4 U6 promoter-shRNA cassette was transferred into
pEind-RNAi by gateway clonase recombination reaction (In-
vitrogen). shRNA against the p53 gene was designed based on a
published sequence (11). shRNA against firefly luciferase (9)
served as a nonspecific control.
Cell Culture, Retroviral Transductions, and Selection of Stable Cells.
U87MG (human glioblastoma-derived cells, ATTC HTB-14)
was maintained in DMEM supplemented with 10% FBS, 0.1
mgml penicillin and 0.1 mgml streptomycin (Life Technolo-
gies, Rockville, MD). The murine endothelial cell line, mHEVc,
was grown in RPMI medium 1640 supplemented with 10%
FBS1 mM Hepes10 mM sodium bicarbonate2 mM glu-
tamine. U87MG stably expressing receptors VgEcR and RXR
(17) was maintained in a puromycin (0.4 mgml) and G418 (1
gml) selection, whereas mHEVc was maintained in puromycin
(0.6 mgml) and G418 (6 gml). Both of the host cell lines
carrying pEind-RNAi were maintained in hygromycin at 0.1
mgml. For biosafety purposes the pEind-RNAi is a self-
inactivating (sin) retrovirus that lacks U3 enhancers in the 3
long terminal repeat (LTR). On proviral integration, this dele-
tion flanks the retroviral insert, thereby removing the enhancers
from both 5 and 3 LTRs minimizing the risk of generating
replication-competent recombinants.
High-titer virus were produced by calcium phosphate trans-
fection of retroviral DNA constructs into the LinX amphotro-
phic retroviral packaging cell line (17) followed by incubation
with dexamethasone and butyrate (each 1 M) of packagers at
32°C for 3 days. Infections were carried out by harvesting
supernatants from LinX packagers, filtered through a 0.45 M
membrane (Millipore), followed by the addition of polybrene (8
M) to supernatants, finally overlaying onto actively dividing
host cells (70% confluent). Cells were gently spun at room
temperature for 30 min and incubated at 32°C for 6 h. Recipients
were infected one more time by using freshly prepared super-
natant from the same packaging plate, at 8-h intervals. At 24 h
after the final infection, cells were split to lower densities and
antibiotic selection applied for 2–3 days. Cells were split on
six-well plates and induced with 2 M murA, and the top 3% of
GFP cells were collected by FACS. Cells that expressed EGFP
in the absence of inducer (2%) were removed by FACS. The
GFP cells were expanded for further analysis. An equal amount
of ethanol was added to the plates that were uninduced. Given
the low percentage of ‘‘leaky’’ cells in the absence of the inducer,
one round of FACS for isolating GFP cells should suffice for
routine applications. However, in experiments requiring long-
term cultures the removal of ‘‘leaky’’ cells may be necessary
where constitutive suppression of a gene (for example, a tumor
suppressor) may confer growth advantage to the cell in the
absence of the inducer.
Western Blot Analysis and Antibodies. Stable cell lines inducibly
expressing shRNAs targeting human p53 or murine MyoD
mRNA were separately grown in six-well plates at a density of
0.3  105 per well. Cells were induced with the indicated
concentrations of murA; and, 72 h after induction, cells were
harvested and lysed with RIPA lysis buffer (150 mM NaCl50
mM Tris, pH 8.00.5% sodium deoxycholate0.1% SDS1%
Nonidet P-40) containing complete protease inhibitor (Roche
Applied Science). Equal amounts of lysate were subjected to
Western blot analysis (20) by using antibodies against p53
(1:1,000, NovoCastra, Newcastle, U.K.), MyoD (1:500), GAL4
(1:1,000), p21 (1:500), EGFP (1:200), and horseradish peroxi-
dase-conjugated secondary antibody (1:5,000), obtained from
Santa Cruz Biotechnology. The blots were stripped by incubating
with 100 mM -mercaptoethanol2% SDS62.5 mM TrisHCl
(pH 6.7) at 50°C for 20 min and reprobed with anti--tubulin
(1:5,000, Sigma) primary antibody and horseradish peroxidase-
conjugated secondary antibody (1:3,000, Amersham Bio-
sciences) to show equal loading. The blots were developed
by using ECL Plus (Amersham Biosciences) or West Femto
(Pierce) blotting detection system. Signal intensities were deter-
mined after background corrections by using ALPHA-IMAGER 2000
documentation and analysis software (Alpha Innotech, San
Leandro, CA). The percentage reduction in band intensity for
each concentration of murA was calculated relative to the
uninduced samples and normalized against -tubulin.
Northern Blot Analysis. Cells were plated at a density of 1  105
in a 10-cm dish and induced with 5 M murA. After 72 h cells
were harvested and total RNA was extracted by using a RNeasy
kit (Qiagen, Valencia, CA). RNA (30 g) was loaded on a 15%
denaturing polyacrylamide-urea gel and Northern blot analysis
was performed (21). A 21-nt sense strand of p53 (GACTC-
CAGTGGTAATCTACTT) was end-labeled with [-32P]ATP
by using a KinaseMax kit (Ambion, Austin, TX). Hybridization
was performed with a NorthernMax kit (Ambion). After hy-
bridization, blots were washed and exposed to x-ray film at
70°C.
Immunofluoresence. U87MG cells stably and inducibly expressing
human p53 shRNA or nonspecific shRNA were separately grown
on glass coverslips in a 12-well plate at a density of 1  103 cells
per well. Nonspecific shRNA was targeted against the Luciferase
gene. Cells were induced with 5 M murA for 72 h, fixed in 4%
paraformaldehyde for 30 min, and washed three times for 5 min
with PBS, followed by permeabilization in 0.2% Triton X-100
and 0.5% normal goat serum for 10 min. The permeabilized cells
were blocked for 30 min in 10% normal goat serum, incubated
with p53 antibody (1:200, NovoCastra) and -tubulin (1:400,
Sigma) for 1 h at room temperature, and washed three times for
5 min with PBS and 0.5% normal goat serum. Next, cells were
incubated with secondary antibodies, Alexa 488 and Alexa 594
(Molecular Probes), for 1 h at room temperature and stained
with 4,6-diamidino-2-phenylindole (1gml). The coverslip was
mounted on antifade mounting medium (Fluoromount-G,
Southern Biotechnology Associates) and visualized under a
fluorescent microscope. Images were captured by using a Zeiss
AxioCam HRm camera at equal exposure time for all panels.
Flow Cytometric Analysis of Cell Cycle Distribution. U87MG cells
stably and inducibly expressing human p53 shRNA were plated
at a density of 1 105 cells per well in six-well plates and induced
with 5 M murA for 72 h followed by -irradiation at 20 Gy. In
reversal experiments cells were trypsinized and replated to
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maintain appropriate densities. Twenty-four hours after -irra-
diation, adherent cells were harvested, washed once in PBS, and
fixed in ice-cold 70% ethanol in distilled water. Cells were then
washed twice in PBS supplemented with 1% BSA and resus-
pended in PBS containing 0.1% Triton X-100, 50 gml pro-
pidium iodide, 5 mM sodium citrate, and 50 gml RNase A.
After incubation at room temperature for 20 min, cells were
analyzed for cell cycle distribution with an LSRII flow cytometer
(Becton Dickinson) and FACSDIVA software (Becton Dickinson).
Red fluorescence (585 42 nm) was evaluated on a linear scale,
and pulse width analysis was used to exclude cell doublets and
aggregates from the analysis. Cells with DNA content between
2N and 4N were designated as being in the G1, S, or G2M phase
of the cell cycle. The number of cells in each compartment of the
cell cycle was expressed as a percentage of the total number of
cells present.
Results and Discussion
Design and Characterization of the Retroviral-Based, Ecdysone-Induc-
ible RNAi System. The U6 promoter is widely used for directing
expression of shRNAs because it is active in all cell types and
efficiently directs synthesis of small, noncoding transcripts bear-
ing well defined ends. However, so far, attempts to generate
robust inducible RNA polymerase III promoters have met with
less than satisfactory results (22). To facilitate stable and induc-
ible suppression of any gene we developed an ecdysone-inducible
synthesis of shRNAs under the control of a modified U6
promoter. We accomplished this by replacing the natural U6
enhancers with heterologous GAL4-DNA-binding sites and
tested GAL4-transactivator fusions (18), which activate tran-
scription specifically from the wild-type U6 promoter but not
from pol II mRNA, U1 small nuclear RNA, or U6 TATA
promoters. A synthetic transactivator, Oct-2Q(Q 3 A), specif-
ically expressed shRNA with no background expression in the
absence of the inducer and was, therefore, used for further
analysis.
The ecdysone-inducible system is composed of three Moloney
murine leukemia virus-based retroviral vectors: the two vectors
expressing nuclear receptorstranscription factors VgEcR and
RXR and a third construct, pEind-RNAi, expressing a chimeric
transactivator GAL4-Oct-2Q(Q3 A) and an internal ribosomal
entry site-linked enhanced GFP (EGFP) under an inducible
promoter hybrid ecdysone-responsive elementHsmin (Fig. 1A).
GFP expression permits enrichment of transduced cells by
fluorescence-activated cell sorting (FACS). We incorporated a
‘‘gateway’’ site-specific acceptor, ccdB (Invitrogen), so that any
DNA-encoded shRNA of interest can be readily transferred
from a donor vector by recombination downstream of the U6
promoter. The enhancer of the U6 promoter comprises an
octamer motif and an adjacent element that binds the transac-
tivators Oct-1 and staf, respectively (23). We deleted the natural
enhancer region and engineered four tandem GAL4-binding
sites (4XGAL4) in its place. On induction with muristerone A
(murA, an analogue of ecdysone), the two receptors
transcription factors dimerize and bind to the hybrid ecdysone-
responsive element to activate GAL4-Oct-2Q(Q 3 A) expres-
sion. GAL4-Oct-2Q(Q 3 A) in turn binds to the 4XGAL4
DNA-binding sites and activates the U6 promoter, which drives
expression of a shRNA (Fig. 1 A).
Stable cell lines were generated as described in Materials and
Methods (also see Fig. 5, which is published as supporting
information on the PNAS web site). The use of a retroviral
delivery and flow sorting of EGFP cells expedited rapid and
efficient generation of stable cell lines both in murine and human
cells. Analysis of sorted cells after induction with murA showed
95% EGFP cells as determined by fluorescent microscopy
(Fig. 1B) and FACS (Fig. 1C). Western blot analysis demon-
strated increased levels of GAL4-Oct-2Q(Q 3 A) and EGFP
protein in samples treated with murA but not in untreated
controls (Fig. 1D). Having established inducible expression of
the activator GAL4-Oct-2Q(Q 3 A), we next demonstrated its
ability to activate p53 shRNA expression from the modified U6
promoter. Northern blot analysis showed production of 21-nt
siRNAs specifically in the cells expressing the activator (Fig. 1E).
These results indicate that the GAL4-Oct-2Q(Q 3 A) induced
formation of the stem-loop precursor transcript that was cleaved
in the cell to produce a functional siRNA. Taken together, these
data indicate that the induction is highly specific and lacks
detectable background expression levels in the absence of the
inducer.
Fig. 1. Design of retroviral vectors for ecdysone-inducible synthesis of shRNA
and experimental validation in mammalian cells. (A) Vector descriptions.
pVgEcR-MP, retroviral vector for constitutive expression of a modified Dro-
sophila ecdysone receptor (containing the VP16 transactivating domain) from
the LTR and marked with a puromycin resistance gene; pRXR-MN, retroviral
vector for constitutive expression of the RXR from the LTR and marked with
the neomycin (G418) resistance gene; pEind-RNAi, a self-inactivating retrovi-
ral ecdysone-inducible vector marked with hygromycin resistance gene;
EGRE, hybrid ecdysone response element; Hsmin, minimal heat shock pro-
moter; IRES, internal ribosomal entry site; PUR, puromycin; NEO, G418 resis-
tance gene; Tkp, enhancerless thymidine kinase promoter; PGK, phosphoglu-
cokinase promoter; ccdB, Gateway system cassette. (B) Microscopic analysis of
a representative cell line to show GFP cells in the absence of murA (murA)
and presence of 0.5 M murA (murA) at 72 h after induction. (C) FACS
analysis to show GFP cells in the absence (murA) and presence (murA) of
5 M murA at 72 h after induction. (D) Western blot analysis showing expres-
sion of EGFP and GAL4-Oct-2Q(Q 3 A) in uninduced cells (lane 1) and cells
induced with 5 M MurA (lane 2) for 72 h. (E) Northern blot analysis showing
inducible expression of p53-specific siRNAs in cells treated with 5M murA for
72 h by probing with 32P-labeled p53 sense strand. 18S RNA served as an
internal control to show equal loading.
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Stable and Efficient RNAi-Mediated Inducible Suppression of Human
p53 Gene. The usefulness of the RNAi-inducible system in
suppressing expression of a cognate target gene was evaluated
next. As a first target we chose the human p53 gene because of
detectable expression in mammalian cells, availability of reliable
antibodies to monitor levels of the protein, and the presence of
an effective shRNA against the p53 gene (11). A human glio-
blastoma cell line, U87MG, carrying a functional wild-type p53
(24) and stably expressing receptors VgEcR and RXR was
transduced with a pEind-RNAi virus expressing an shRNA
targeting the p53 gene. Stable cells treated with 0.5–5 M murA
showed a dose-dependent reduction in endogenous p53 level
with almost 95% reduction in the presence of 5 M murA (Fig.
2A Upper). The suppression of p53 was also time-dependent,
showing partial reduction (60%) at 48 h and maximal reduction
(95%) at 72 h after induction (Fig. 2B). To ascertain that the
induced shRNA targeted the p53 mRNA specifically, we mea-
sured the levels of cyclin-dependent kinase inhibitor p21, a well
characterized transcriptional target of p53. As expected, the
decrease in p21 levels correlated well with inducible suppression
of p53 (Fig. 2 A Upper), relative to that obtained with a nonspe-
cific shRNA (Fig. 2 A Lower). In contrast, levels of Cdk4 protein,
an upstream component of the p53-signaling pathway, remained
unchanged (data not shown). Taken together, these results
suggest that the p53 shRNA synthesized by the inducible system
is tightly regulated and exhibits high target specificity.
We next assessed the effects of inducing expression of p53
shRNA at a single-cell level by immunofluorescence experi-
ments. The results showed the presence of nuclear p53 in the
absence of induction (Fig. 2C Upper, top row), as expected.
Induction of p53 shRNA expression resulted in a dramatic
reduction in the levels of p53 (Fig. 2C Upper, bottom row),
relative to that obtained with a nonspecific shRNA (Fig. 2C
Lower). Cells with reduced levels of p53 were flat and large in
contrast to normal long-spindle forms observed in the uninduced
state (Fig. 2C Upper). The morphological change was specific to
effects of p53 hairpin and not to the activity of either the inducer
or the expression of GAL4-Oct-2Q(Q 3 A), EGFP, and non-
specific shRNA (Fig. 2C Lower). Although reports indicating
morphology changes in HeLa cells as a consequence of p53
suppression by antisense RNA are available (25), it is likely that
in the U87MG cells’ suppression of p53 cooperates with the
absence of PTEN (26, 27) to generate the observed phenotype.
After having established specific down-regulation of p53 gene
Fig. 2. Stable and efficient RNAi-mediated inducible suppression of human p53 gene in U87MG cells. (A) Dose–response of ecdysone-inducible RNAi. Stable
cell lines carrying p53-specific shRNA (p53-SP) and nonspecific shRNA (NON-SP) were induced with 0.0 (lane 1), 0.5 (lane 2), 2.0 (lane 3), 3.0 (lane 4), and 5.0 (lane
5) M murA. Whole-cell extracts were prepared after 72 h and analyzed by Western blotting for p53, p21, and -tubulin (control). Fold reduction in p53 protein
level is 30% (lane 2), 64% (lane 3), 90% (lane 4), and 95% (lane 5) relative to uninduced sample (lane 1). (B) Time course of ecdysone-inducible RNAi. Stable
cells carrying shRNA for p53 were induced with 5M murA and analyzed for p53 levels at indicated time points; fold reduction of p53 protein level is 60% (murA
at 48 h) and95% (murA at 96 h). Fold reduction of protein level was based on densitometric measurement. (C) Inducible suppression of p53 at a single-cell
level by immunofluorescence, showing silencing of p53 gene by an inducible p53 shRNA in the presence of 5M murA (Upper, bottom row) but not in the absence
of murA (Upper, top row), 72 h after induction. Staining with p53-specific antibody (red) and -tubulin (green). 4,6-Diamidino-2-phenylindole (DAPI) was used
to stain nuclei (blue). (D) Cell cycle analysis of -irradiated U87MG cells carrying inducible p53 shRNA by FACS. Stable cell lines carrying p53 shRNA were either
uninduced (murA) or induced (murA) with 5 M murA for 72 h and subjected to 20 Gy of -irradiation. After 24 h FACS analysis showing distribution of cells
in G1, S, and G2M phases of the cell cycle is shown. IR, irradiation. This experiment is a representation of three independent data sets.
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expression by inducible RNAi, we next wondered whether the
p53 suppression had a functional consequence. FACS analysis
showed a dramatic increase in the cell number in G2M phase
(39%) and a concomitant decrease in G0G1 phase (40%) in
uninduced, irradiated samples (Fig. 2D Upper Right). In contrast,
cells induced for p53 shRNA and exposed to -irradiation lost
their ability to arrest at the G2M phase of the cell cycle (Fig. 2D
Lower Right). We were unable to observe G0G1 arrest in
multiple independent experiments, underscoring the importance
of p53 in mediating G2M arrest in response to DNA damage in
U87MG cells consistent with published observations (28, 29).
Indeed, cell cycle arrest in G2M has been shown to depend on
the cell type (30, 31).
The RNAi-Mediated Inducible Gene Suppression Is Reversible. A
major limitation of constitutive shRNA expression systems is the
irreversible suppression of gene expression that could result in
nonphysiological responses. We determined whether the gene
suppression obtained by the RNAi-inducible system could be
reversed after withdrawal of the inducer. In the presence of the
inducer stable cells carrying p53 shRNA showed, as expected,
reduction in endogenous p53 levels (Fig. 3A) and associated
morphological changes at 72 h after induction (Fig. 3B). On
removal of the inducer a partial recovery occurred in p53 protein
levels at 48 h, with almost full recovery at 96 h (Fig. 3A). The
recovery of p53 protein level was associated with restoration in
the original cell morphology (Fig. 3B, compare large flat cells at
72 h in the presence of murA with spindle-shaped cells at 96 h
after withdrawal of murA), and cell function as determined by
-irradiation induced cell cycle arrest (see Fig. 6, which is
published as supporting information on the PNAS web site),
underscoring the swift clearance kinetics of murA that results in
a rapid phenotypic switch. These studies also demonstrate that
the p53 gene suppression does not lead to an irreversible cascade
of molecular events.
Inducible Suppression of MyoD in a Murine Cell line. The general
utility of the RNAi-inducible system was determined by target-
ing suppression of a MyoD gene in a murine cell line. Murine
endothelial cells, mHEVc (32), were transduced with viruses
carrying the two receptorstranscription factors and pEind-
RNAi expressing a MyoD shRNA, as described earlier. Efficient
suppression of MyoD gene expression was observed at 72 h after
induction (Fig. 4A). Furthermore, increasing concentrations of
murA (0.5–5 M) showed a dose-dependent reduction in en-
dogenous MyoD levels with almost 95% reduction in the pres-
ence of 5 M murA (Fig. 4B Upper), relative to cells stably
expressing a nonspecific shRNA (NON-SP, Fig. 4B Lower).
In summary, we provide a powerful approach to stably and
inducibly suppress gene expression in mammalian cells. Given
the success of the ecdysone-based inducible systems in animal
models (15, 33) and germ-line transmission of RNAi (34), it is
conceivable to generate transgenic animals inducibly expressing
RNAi. A considerable improvement to the existing design would
be to obtain tissue-specific regulation in vivo by either expressing
the GAL4 activator under the control of a tissue-specific pro-
moter or by using a ‘‘caged ecdysteroid’’ (35). Recently, doxy-
cyclin-controllable suppression of genes in mammalian cells was
reported (36, 37). However, it was not clear how much basal
expression in the absence of the inducer these systems allow.
Furthermore, doxycyclin is linked to toxicity problems, a major
disadvantage for studies involving both cultured cells and ani-
mals. Ecdysone is more suitable for use in vivo because it is a
naturally occurring lipophilic steroid that can penetrate tissues
and is quickly metabolized and cleared (33).
A major application of the RNAi-inducible system would be
in studies where partial down-regulation of gene expression is
desired, in particular, in cases where partial suppression results
in distinct phenotypes. For example, shRNAs showing varying
levels of p53 suppression generated distinct tumor phenotypes in
Fig. 3. RNAi-mediated inducible gene suppression is reversible. (A) Western
blot analysis showing 93% fold reduction in p53 protein levels in cells induced
with 5 M murA (murA) relative to uninduced (murA) at 72 h. After murA
removal, the fold recovery in p53 levels is 20% (48 h) and 90% (96 h). (B)
Phase-contrast microscopy showing morphology of U87MG cells either unin-
duced (murA) or induced with 5 M murA (murA) for 72 h and at 48 and
96 h after murA removal.
Fig. 4. Inducible suppression of MyoD gene expression in a murine endo-
thelial cells. (A) Cells stably and inducibly expressing MyoD shRNA (MyoD-SP)
and nonspecific shRNA (NON-SP) were treated with 5 M murA. Whole-cell
extracts were prepared at 72 h after induction and analyzed by Western blot
for MyoD and -tubulin. Fold reduction of protein level is 95% for MyoD
(MyoD-SP) relative to nonspecific shRNA. (B) Stable cells carrying MyoD spe-
cific shRNA (MyoD-SP) and nonspecific shRNA (NON-SP) were induced with 0.0
(lane 1), 0.5 (lane 2), 1.0 (lane 3), 3.0 (lane 4), and 5.0 (lane 5) M murA and
subjected to Western blot for MyoD and -tubulin. Fold reduction of MyoD
protein level for shRNA (MyoD-SP) is 5% (lane 2), 25% (lane 3), 72% (lane 4),
and 95% (lane 5) relative to uninduced sample (lane 1). Fold reduction in
MyoD was normalized against -tubulin for each band. shRNA used for the
suppression of MyoD gene expression was identified in a high-throughput
screen (19).
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vivo (38). Partial suppression is also useful where lethality associ-
ated with complete suppression of essential genes is of concern. In
our system, the levels of shRNA expression can be easily and finely
controlled by simply varying the dosage of the inducer.
We thank Nouria Hernandez for comments on the manuscript and
helpful discussions and Winship Herr, Zaher Nahle, Douglas Conklin,
Linda Rodgers, Elisa De Stanchina, Lance Palmer, and Kimberly
LaVine for reagents.
1. Hammond, S. M., Boettcher, S., Caudy, A. A., Kobayashi, R. & Hannon, G. J.
(2001) Science 293, 1146–1150.
2. Sharp, P. A. (1999) Genes Dev. 13, 139–141.
3. Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K. & Tuschl,
T. (2001) Nature 411, 494–498.
4. Bernstein, E., Caudy, A. A., Hammond, S. M. & Hannon, G. J. (2001) Nature
409, 363–366.
5. Paddison, P. J. & Hannon, G. J. (2002) Cancer Cell 2, 17–23.
6. Marcus, P. I. & Sekellick, M. J. (2001) J. Interferon Cytokine Res. 21, 423–429.
7. Gil, J. & Esteban, M. (2000) Apoptosis 5, 107–114.
8. Elbashir, S. M., Harborth, J., Weber, K. & Tuschl, T. (2002) Methods 26,
199–213.
9. Paddison, P. J., Caudy, A. A., Bernstein, E., Hannon, G. J. & Conklin, D. S.
(2002) Genes Dev. 16, 948–958.
10. Sui, G., Soohoo, C., Affar el, B., Gay, F., Shi, Y. & Forrester, W. C. (2002) Proc.
Natl. Acad. Sci. USA 99, 5515–5520.
11. Brummelkamp, T. R., Bernards, R. & Agami, R. (2002) Science 296,
550–553.
12. Paul, C. P., Good, P. D., Winer, I. & Engelke, D. R. (2002) Nat. Biotechnol. 20,
505–508.
13. Rubinson, D. A., Dillon, C. P., Kwiatkowski, A. V., Sievers, C., Yang, L.,
Kopinja, J., Zhang, M., McManus, M. T., Gertler, F. B., Scott, M. L. & Van
Parijs, L. (2003) Nat. Genet. 33, 401–406.
14. Gossen, M., Freundlieb, S., Bender, G., Muller, G., Hillen, W. & Bujard, H.
(1995) Science 268, 1766–1769.
15. No, D., Yao, T. P. & Evans, R. M. (1996) Proc. Natl. Acad. Sci. USA 93,
3346–3351.
16. Van Craenenbroeck, K., Vanhoenacker, P., Leysen, J. E. & Haegeman, G.
(2001) Eur. J. Neurosci. 14, 968–976.
17. Stolarov, J., Chang, K., Reiner, A., Rodgers, L., Hannon, G. J., Wigler, M. H.
& Mittal, V. (2001) Proc. Natl. Acad. Sci. USA 98, 13043–13048.
18. Das, G., Hinkley, C. S. & Herr, W. (1995) Nature 374, 657–660.
19. Kumar, R., Conklin, D. S. & Mittal, V. (2003) Genome Res. 13, 2333–2340.
20. Harlow, E. & Lane, D. (1988) Antibodies, A Laboratory Manual. (Cold Spring
Harbor Lab. Press, Plainview, NY).
21. Dalmay, T., Hamilton, A., Rudd, S., Angell, S. & Baulcombe, D. C. (2000) Cell
101, 543–553.
22. Meissner, W., Rothfels, H., Schafer, B. & Seifart, K. (2001) Nucleic Acids Res.
29, 1672–1682.
23. Schaub, M., Myslinski, E., Schuster, C., Krol, A. & Carbon, P. (1997) EMBO
J. 16, 173–181.
24. Van Meir, E. G., Kikuchi, T., Tada, M., Li, H., Diserens, A. C., Wojcik, B. E.,
Huang, H. J., Friedmann, T., de Tribolet, N. & Cavenee, W. K. (1994) Cancer
Res. 54, 649–652.
25. Iotsova, V. & Stehelin, D. (1995) Eur J. Cell Biol. 68, 122–132.
26. Mayo, L. D., Dixon, J. E., Durden, D. L., Tonks, N. K. & Donner, D. B. (2002)
J. Biol. Chem. 277, 5484–5489.
27. Stambolic, V., MacPherson, D., Sas, D., Lin, Y., Snow, B., Jang, Y., Benchimol,
S. & Mak, T. W. (2001) Mol. Cell 8, 317–325.
28. Badie, B., Goh, C. S., Klaver, J., Herweijer, H. & Boothman, D. A. (1999)
Cancer Gene Ther. 6, 155–162.
29. Hirose, Y., Berger, M. S. & Pieper, R. O. (2001) Cancer Res. 61, 1957–1963.
30. Taylor, W. R. & Stark, G. R. (2001) Oncogene 20, 1803–1815.
31. Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P.,
Sedivy, J. M., Kinzler, K. W. & Vogelstein, B. (1998) Science 282, 1497–1501.
32. Tudor, K. S., Deem, T. L. & Cook-Mills, J. M. (2000) Biochem. Cell Biol. 78,
99–113.
33. Karns, L. R., Kisielewski, A., Gulding, K. M., Seraj, J. M. & Theodorescu, D.
(2001) BMC Biotechnol. 1, 1–12.
34. Carmell, M. A., Zhang, L., Conklin, D. S., Hannon, G. J. & Rosenquist, T. A.
(2003) Nat. Struct. Biol 10, 91–92.
35. Lin, W., Albanese, C., Pestell, R. G. & Lawrence, D. S. (2002) Chem. Biol. 9,
1347–1353.
36. Wiznerowicz, M. & Trono, D. (2003) J. Virol. 77, 8957–8961.
37. van de Wetering, M., Oving, I., Muncan, V., Pon Fong, M. T., Brantjes, H., van
Leenen, D., Holstege, F. C., Brummelkamp, T. R., Agami, R. & Clevers, H.
(2003) EMBO Rep. 4, 609–615.
38. Hemann, M. T., Fridman, J. S., Zilfou, J. T., Hernando, E., Paddison, P. J.,
Cordon-Cardo, C., Hannon, G. J. & Lowe, S. W. (2003) Nat. Genet. 33,
396–400.
1932  www.pnas.orgcgidoi10.1073pnas.0306111101 Gupta et al.
